person · Reporting owner

Alleva Lawrence M

Disclosed activity across 6 companies

Tapewire entity: 26161
SEC CIK: 0001553053

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Adaptimmune Therapeutics PLCADAP · Entity 9824	Director	July 01, 2024	July 01, 2024
BRIGHT HORIZONS FAMILY SOLUTIONS INC.BFAM · Entity 531	Director	June 03, 2026	June 05, 2026
SYNLOGIC, INC.MIRN · Entity 7801	Director	June 29, 2016	September 06, 2016

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adaptimmune Therapeutics PLC

Report date July 01, 2024 · Filed July 01, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.16 · Expires 2034-07-01	Direct	1,213,926	Reported balance After 2024-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-07-01 · Grant · Acquired 1,213,926 · Balance 1,213,926 F1: The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount.

BRIGHT HORIZONS FAMILY SOLUTIONS INC.

Report date June 03, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,336	Reported balance After 2026-06-03 transaction · row 1 1 source row Row 1 · 2026-06-03 · Grant · Acquired 2,096 · Balance 13,336 F1: Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company.

SYNLOGIC, INC.

Report date June 29, 2016 · Filed September 06, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.74 · Expires 2026-06-29	Direct	10,000	Reported balance After 2016-06-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-06-29 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Galera Therapeutics, Inc.

Report date August 03, 2026 · Filed August 05, 2026

Section 16 reporting ended · disclosed 2026-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-08-03 transaction · row 1 1 source row Row 1 · 2026-08-03 · Disposition to issuer · Disposed 11 · Balance 0 F1: These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. ("Galera") effected on July 12, 2026. F2: Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the "Merger Agreement"), by and among Galera, Obsidian Therapeutics, Inc. ("Obsidian"), Gazelle Parent, Inc. ("Parent"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent ("Obsidian Merger Sub"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Galera Merger Sub"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the "Galera Merger"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the "Mergers"). F3: At the effective time of the Galera Merger (the "Galera Effective Time"), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the "Galera Exchange Ratio").
Common StockSEC Table I · non-derivative	IndirectBy the Lawrence M. Alleva Revocable Trust.	Reported balance After 2026-08-03 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-08-03 · Disposition to issuer · Disposed 40 · Balance 0 F1: These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. ("Galera") effected on July 12, 2026. F2: Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the "Merger Agreement"), by and among Galera, Obsidian Therapeutics, Inc. ("Obsidian"), Gazelle Parent, Inc. ("Parent"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent ("Obsidian Merger Sub"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Galera Merger Sub"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the "Galera Merger"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the "Mergers"). F3: At the effective time of the Galera Merger (the "Galera Effective Time"), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the "Galera Exchange Ratio").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2035-02-23	Direct	Reported balance After 2026-08-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-03 · Disposition to issuer · Disposed 240 · Balance 0 F1: These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. ("Galera") effected on July 12, 2026. F2: Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the "Merger Agreement"), by and among Galera, Obsidian Therapeutics, Inc. ("Obsidian"), Gazelle Parent, Inc. ("Parent"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent ("Obsidian Merger Sub"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Galera Merger Sub"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the "Galera Merger"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the "Mergers"). F4: At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an "In-the-Money Option"), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. ("Galera") effected on July 12, 2026.

F2: Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the "Merger Agreement"), by and among Galera, Obsidian Therapeutics, Inc. ("Obsidian"), Gazelle Parent, Inc. ("Parent"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent ("Obsidian Merger Sub"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Galera Merger Sub"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the "Galera Merger"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the "Mergers").

F3: At the effective time of the Galera Merger (the "Galera Effective Time"), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the "Galera Exchange Ratio").

F4: At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an "In-the-Money Option"), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.

Mersana Therapeutics, Inc.

Report date January 06, 2026 · Filed January 06, 2026

Section 16 reporting ended · disclosed 2026-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-01-06 transaction · row 1 1 source row Row 1 · 2026-01-06 · Other · Disposed 578 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2026-01-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-01-06 · Other · Disposed 84 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F5: The securities were held directly by the Lawrence M. Alleva Revocable Trust.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08	Direct	Reported balance After 2026-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-01-06 · Disposition to issuer · Disposed 2,460 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $437.50	Direct	Reported balance After 2026-01-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-06 · Disposition to issuer · Disposed 800 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $434.75	Direct	Reported balance After 2026-01-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-06 · Disposition to issuer · Disposed 142 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $306.75	Direct	Reported balance After 2026-01-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-06 · Disposition to issuer · Disposed 400 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.75	Direct	Reported balance After 2026-01-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-06 · Disposition to issuer · Disposed 544 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.75	Direct	Reported balance After 2026-01-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-01-06 · Disposition to issuer · Disposed 1,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $134.00	Direct	Reported balance After 2026-01-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-01-06 · Disposition to issuer · Disposed 450 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $572.50	Direct	Reported balance After 2026-01-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-01-06 · Disposition to issuer · Disposed 368 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $527.25	Direct	Reported balance After 2026-01-06 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-01-06 · Disposition to issuer · Disposed 133 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $372.50	Direct	Reported balance After 2026-01-06 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-01-06 · Disposition to issuer · Disposed 1,002 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.00	Direct	Reported balance After 2026-01-06 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-01-06 · Disposition to issuer · Disposed 546 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.50	Direct	Reported balance After 2026-01-06 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-01-06 · Disposition to issuer · Disposed 1,800 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.25	Direct	Reported balance After 2026-01-06 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2026-01-06 · Disposition to issuer · Disposed 181 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $216.00	Direct	Reported balance After 2026-01-06 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2026-01-06 · Disposition to issuer · Disposed 734 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.50	Direct	Reported balance After 2026-01-06 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2026-01-06 · Disposition to issuer · Disposed 215 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.50	Direct	Reported balance After 2026-01-06 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2026-01-06 · Disposition to issuer · Disposed 561 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.75	Direct	Reported balance After 2026-01-06 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2026-01-06 · Disposition to issuer · Disposed 310 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $110.50	Direct	Reported balance After 2026-01-06 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2026-01-06 · Disposition to issuer · Disposed 159 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.50	Direct	Reported balance After 2026-01-06 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2026-01-06 · Disposition to issuer · Disposed 2,200 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.25	Direct	Reported balance After 2026-01-06 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2026-01-06 · Disposition to issuer · Disposed 358 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.75	Direct	Reported balance After 2026-01-06 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2026-01-06 · Disposition to issuer · Disposed 384 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.00	Direct	Reported balance After 2026-01-06 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2026-01-06 · Disposition to issuer · Disposed 500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F5: The securities were held directly by the Lawrence M. Alleva Revocable Trust.

TESARO, Inc.

Report date January 22, 2019 · Filed January 22, 2019

Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-01-22 transaction · row 1 1 source row Row 1 · 2019-01-22 · Other · Disposed 29,902 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
Director Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-01-22 · Disposition to issuer · Disposed 4,052 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.62 · Expires 2022-04-27	Direct	Reported balance After 2019-01-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-01-22 · Disposition to issuer · Disposed 21,428 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.22 · Expires 2023-06-03	Direct	Reported balance After 2019-01-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-01-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.36 · Expires 2024-06-02	Direct	Reported balance After 2019-01-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-01-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.77 · Expires 2025-06-01	Direct	Reported balance After 2019-01-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-01-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.27 · Expires 2026-06-01	Direct	Reported balance After 2019-01-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.22 · Expires 2027-06-01	Direct	Reported balance After 2019-01-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.89 · Expires 2028-06-01	Direct	Reported balance After 2019-01-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-01-22 · Disposition to issuer · Disposed 7,209 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Filing footnotes · ownership attribution and instrument terms

F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").

F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 01, 2022 Filed Jul 1, 2022 21:03 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	816,067	$0.00 Strike: $0.28	$0.00	Disclosure SEC source: 0001104659-22-076900 · tm2220260-6_4seq1.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,067 Underlying: Ordinary Shares · 816,067 shares Expires 2032-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
June 22, 2022 Filed Jun 23, 2022 20:53 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	GrantCommon Stock	1,299	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-22-005325 · primarydocument.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,955 F1 · price: Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Read SEC document
June 15, 2022 Filed Jun 16, 2022 20:05 UTC	Galera Therapeutics, Inc. GRTX · Entity 15899	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $1.48	$0.00	Disclosure SEC source: 0000899243-22-022793 · doc4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:21 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	45,000	$0.00 Strike: $3.62	$0.00	Disclosure SEC source: 0001104659-22-070144 · tm2218135-6_4seq1.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: The option will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders of Mersana Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. Read SEC document
January 03, 2022 Filed Jan 5, 2022 22:04 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	13,657	$0.00 Strike: $6.44	$0.00	Disclosure SEC source: 0001104659-22-001556 · tm221771-3_4seq1.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,657 Underlying: Common Stock · 13,657 shares Expires 2032-01-02 F1 · derivative.exercise_date: The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2022. Read SEC document
July 01, 2021 Filed Jul 2, 2021 21:03 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	505,918	$0.00 Strike: $0.71	$0.00	Disclosure SEC source: 0001104659-21-088972 · tm2121284-6_4seq1.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,918 Underlying: Ordinary Shares · 505,918 shares Expires 2031-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
July 01, 2021 Filed Jul 6, 2021 22:15 UTC	Galera Therapeutics, Inc. GRTX · Entity 15899	GrantStock Option (Right to Buy) · Derivative	8,498	$0.00 Strike: $10.09	$0.00	Disclosure SEC source: 0000899243-21-027604 · doc4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,498 Underlying: Common Stock · 8,498 shares Expires 2031-06-30 F1 · derivative.exercise_date: This option was awarded pursuant to the "elective option" provisions of the Issuer's non-employee director compensation program for the Reporting Peron's service on the Issuer's Board and certain of its committees. This option shall vest and become exercisable as to 25% of the shares subject to the option upon the Reporting Person completing each three months of continuous service as a Non-Employee Director, or in the applicable committee position, following the date of grant, provided that the fourth and final tranche of the option will vest and become exercisable on the earlier of July 1, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director, or in the applicable committee position, through such vesting date. Read SEC document
June 24, 2021 Filed Jun 28, 2021 20:03 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	GrantCommon Stock	671	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-004517 · primarydocument.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,656 F1 · price: Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Read SEC document
June 16, 2021 Filed Jun 17, 2021 22:41 UTC	Galera Therapeutics, Inc. GRTX · Entity 15899	GrantStock Option (Right to Buy) · Derivative	9,888	$0.00 Strike: $8.90	$0.00	Disclosure SEC source: 0000899243-21-024506 · doc4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,888 Underlying: Common Stock · 9,888 shares Expires 2031-06-15 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 16, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document
June 11, 2021 Filed Jun 15, 2021 22:03 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	25,050	$0.00 Strike: $14.90	$0.00	Disclosure SEC source: 0001104659-21-081610 · tm2119714-5_4seq1.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,050 Underlying: Common Stock · 25,050 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2022 Annual Meeting of Stockholders of Mersana Therapeutics, Inc. Read SEC document
June 01, 2021 Filed Jun 3, 2021 22:58 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	PurchaseCommon Stock	1,035	$14.38	$14,883.30	Disclosure SEC source: 0001104659-21-076535 · tm2118511-1_4seq1.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Trust Disclosed balance after: 2,120 F1 · balance_after: In a Form 4 filed on June 3, 2020, the reporting person reported direct beneficial ownership of 1,085 shares of the Company's common stock. Such shares are held directly by the Lawrence M. Alleva Revocable Trust and the nature of the reporting person's interest in such shares is indirect. F2 · ownership.nature: The securities are held directly by the Lawrence M. Alleva Revocable Trust. Read SEC document
June 01, 2021 Filed Jun 3, 2021 21:22 UTC	Galera Therapeutics, Inc. GRTX · Entity 15899	PurchaseCommon Stock	4,045	$8.59	$34,741.29	Disclosure SEC source: 0000899243-21-021824 · doc4.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lawrence M. Alleva Revocable Trust. Disclosed balance after: 4,045 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.587 to $8.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:31 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	PurchaseOrdinary Shares with a nominal value of GBP0.001 per share	12,600	$0.79	$9,954.00	Disclosure SEC source: 0001104659-21-076401 · tm2118429-1_4seq1.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Trust Disclosed balance after: 12,600 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. F2 · shares: The 12,600 ordinary shares reported in Column 4 and Column 5 are represented by 2,100 ADSs. F3 · price: The price reported in Column 4 of $0.79 per ordinary share is derived from the weighted average purchase price paid on June 1, 2021 of $4.745 per ADS divided by six. F2 · balance_after: The 12,600 ordinary shares reported in Column 4 and Column 5 are represented by 2,100 ADSs. Read SEC document
January 15, 2021 Filed Jan 21, 2021 00:00 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	3,339	$0.00 Strike: $21.09	$0.00	Disclosure SEC source: 0001104659-21-005941 · tm211948d1_4seq1.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,339 Underlying: Common Stock · 3,339 shares Expires 2031-01-15 F1 · derivative.exercise_date: The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2021. Read SEC document
November 13, 2020 Filed Nov 17, 2020 21:06 UTC	Galera Therapeutics, Inc. GRTX · Entity 15899	PurchaseCommon Stock	2,325	$10.22	$23,771.27	Disclosure SEC source: 0000899243-20-031268 · doc4.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,325 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.93 to $10.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
July 01, 2020 Filed Jul 1, 2020 21:09 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	197,678	$0.00 Strike: $1.67	$0.00	Disclosure SEC source: 0001104659-20-079789 · a4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,678 Underlying: Ordinary Shares · 197,678 shares Expires 2030-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
June 25, 2020 Filed Jun 30, 2020 00:11 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	9,200	$0.00 Strike: $22.90	$0.00	Disclosure SEC source: 0001104659-20-078229 · a4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2030-06-25 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2021 Annual Meeting of Stockholders of Mersana Therapeutics, Inc. Read SEC document
June 16, 2020 Filed Jun 17, 2020 20:16 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	GrantCommon Stock	801	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-004527 · primarydocument.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,985 F1 · price: Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Read SEC document
June 09, 2020 Filed Jun 10, 2020 21:18 UTC	Galera Therapeutics, Inc. GRTX · Entity 15899	GrantStock Option (Right to Buy) · Derivative	9,888	$0.00 Strike: $9.31	$0.00	Disclosure SEC source: 0000899243-20-015975 · doc4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,888 Underlying: Common Stock · 9,888 shares Expires 2030-06-08 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 9, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document
June 09, 2020 Filed Jun 12, 2020 01:00 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	PurchaseOrdinary Shares with a nominal value of GBP0.001 per share	12,900	$1.89	$24,381.00	Disclosure SEC source: 0001104659-20-072556 · a4.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Trust Disclosed balance after: 12,900 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. F2 · shares: The 12,900 ordinary shares reported in Column 4 and Column 5 are represented by 2,150 ADSs. F3 · price: The price reported in Column 4 of $1.89 per ordinary share is derived from the purchase price paid on June 9, 2020 of $11.354 per ADS divided by six. F2 · balance_after: The 12,900 ordinary shares reported in Column 4 and Column 5 are represented by 2,150 ADSs. Read SEC document
June 01, 2020 Filed Jun 3, 2020 21:30 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	PurchaseCommon Stock	700	$22.94	$16,058.00	Disclosure SEC source: 0001104659-20-069498 · a4.xml · nonDerivative · entry 2 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Read SEC document
June 01, 2020 Filed Jun 3, 2020 21:30 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	PurchaseCommon Stock	385	$22.97	$8,843.45	Disclosure SEC source: 0001104659-20-069498 · a4.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385 Read SEC document
May 19, 2020 Filed May 21, 2020 20:01 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	PurchaseCommon Stock	227	$107.95	$24,504.88	Disclosure SEC source: 0001562180-20-003825 · primarydocument.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,184 Read SEC document
May 11, 2020 Filed May 13, 2020 23:22 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	Exercise / conversionRestricted Stock Units · Derivative	1,000	$0.00	$0.00	Disclosure SEC source: 0001562180-20-003591 · primarydocument.xml · derivative · entry 2 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant. F1 · derivative.exercise_date: Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant. F1 · derivative.expiration_date: Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant. Read SEC document
May 11, 2020 Filed May 13, 2020 23:22 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	Exercise / conversionCommon Stock	1,000	$0.00	$0.00	Disclosure SEC source: 0001562180-20-003591 · primarydocument.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:37 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	11,264	$0.00 Strike: $5.36	$0.00	Disclosure SEC source: 0001104659-20-000910 · a4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,264 Underlying: Common Stock · 11,264 shares Expires 2030-01-02 F1 · derivative.exercise_date: The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2020. Read SEC document
December 13, 2019 Filed Dec 17, 2019 21:05 UTC	Galera Therapeutics, Inc. GRTX · Entity 15899	PurchaseCommon Stock	4,000	$9.78	$39,138.80	Disclosure SEC source: 0000899243-19-029402 · doc4.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.8773, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
July 02, 2019 Filed Jul 3, 2019 21:00 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	271,209	$0.00 Strike: $0.61	$0.00	Disclosure SEC source: 0001104659-19-039321 · a4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,209 Underlying: Ordinary Shares · 271,209 shares Expires 2029-07-02 F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
June 07, 2019 Filed Jun 11, 2019 20:36 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $4.31	$0.00	Disclosure SEC source: 0001104659-19-034799 · a4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-07 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2020 Annual Meeting of Stockholders of Mersana Therapeutics, Inc. Read SEC document
May 29, 2019 Filed May 31, 2019 20:01 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	GrantCommon Stock	739	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003192 · primarydocument.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,957 F1 · price: Each restricted stock unit is fully vested and represents the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Read SEC document
May 12, 2019 Filed May 14, 2019 20:06 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	Exercise / conversionRestricted Stock Units · Derivative	1,011	$0.00	$0.00	Disclosure SEC source: 0001562180-19-002790 · primarydocument.xml · derivative · entry 2 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,011 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant. F1 · derivative.exercise_date: Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant. F1 · derivative.expiration_date: Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant. Read SEC document
May 12, 2019 Filed May 14, 2019 20:06 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	Exercise / conversionCommon Stock	1,011	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-19-002790 · primarydocument.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units are fully vested upon grant and represent the right to receive one share of common stock upon the earliest of the 5th anniversary of the grant, termination of service, and a change in control of the Company. Each restricted stock unit was settled and shares of common stock issued upon the 5th anniversary of the grant. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:55 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative	7,209	Not disclosed Strike: $46.89	Not disclosed	Disclosure SEC source: 0001123292-19-000161 · edgar.xml · derivative · entry 9 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,209 shares Expires 2028-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:55 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative	12,000	Not disclosed Strike: $149.22	Not disclosed	Disclosure SEC source: 0001123292-19-000161 · edgar.xml · derivative · entry 8 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2027-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:55 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative	12,000	Not disclosed Strike: $47.27	Not disclosed	Disclosure SEC source: 0001123292-19-000161 · edgar.xml · derivative · entry 7 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:55 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative	10,000	Not disclosed Strike: $60.77	Not disclosed	Disclosure SEC source: 0001123292-19-000161 · edgar.xml · derivative · entry 6 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:55 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative	10,000	Not disclosed Strike: $26.36	Not disclosed	Disclosure SEC source: 0001123292-19-000161 · edgar.xml · derivative · entry 5 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-06-02 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:55 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative	10,000	Not disclosed Strike: $46.22	Not disclosed	Disclosure SEC source: 0001123292-19-000161 · edgar.xml · derivative · entry 4 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-06-03 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:55 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative	21,428	Not disclosed Strike: $6.62	Not disclosed	Disclosure SEC source: 0001123292-19-000161 · edgar.xml · derivative · entry 3 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,428 shares Expires 2022-04-27 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:55 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerDirector Restricted Stock Units · Derivative	4,052	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-19-000161 · edgar.xml · derivative · entry 2 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,052 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:55 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	29,902	$75.00	$2,242,650.00	Disclosure SEC source: 0001123292-19-000161 · edgar.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). Read SEC document
January 02, 2019 Filed Jan 4, 2019 21:00 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	13,619	$0.00 Strike: $4.31	$0.00	Disclosure SEC source: 0001104659-19-000776 · a4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,619 Underlying: Common Stock · 13,619 shares Expires 2029-01-02 F1 · derivative.exercise_date: The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2019. Read SEC document
December 17, 2018 Filed Dec 20, 2018 01:04 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	PurchaseOrdinary Shares with a nominal value of GBP0.001 per share	47,280	$0.84	$39,715.20	Disclosure SEC source: 0001104659-18-073869 · a4.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Trust Disclosed balance after: 47,280 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. F2 · shares: The 47,280 ordinary shares reported in Column 4 and Column 5 are represented by 7,880 ADSs. F3 · price: The price reported in Column 4 of $0.84 per ordinary share is derived from the purchase price paid on December 17, 2018 of $5.006 per ADS divided by six. F2 · balance_after: The 47,280 ordinary shares reported in Column 4 and Column 5 are represented by 7,880 ADSs. Read SEC document
September 20, 2018 Filed Sep 21, 2018 20:01 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $12.27	$0.00	Disclosure SEC source: 0001104659-18-058010 · a4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-09-20 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2019 Annual Meeting of Stockholders of Mersana Therapeutics, Inc. Read SEC document
August 07, 2018 Filed Aug 7, 2018 20:24 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	Exercise / conversionOption to Purchase Common Stock · Derivative	2,272	$0.00 Strike: $22.00	$0.00	Disclosure SEC source: 0001562180-18-003502 · primarydocument.xml · derivative · entry 6 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,272 shares Expires 2020-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The option to purchase shares is fully vested. Read SEC document
August 07, 2018 Filed Aug 7, 2018 20:24 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	Exercise / conversionOption to Purchase Common Stock · Derivative	3,000	$0.00 Strike: $34.96	$0.00	Disclosure SEC source: 0001562180-18-003502 · primarydocument.xml · derivative · entry 5 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The option to purchase shares is fully vested. Read SEC document
August 07, 2018 Filed Aug 7, 2018 20:24 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	SaleCommon Stock	1,248	$110.37	$137,741.76	Disclosure SEC source: 0001562180-18-003502 · primarydocument.xml · nonDerivative · entry 4 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,207 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $110.30 to $110.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
August 07, 2018 Filed Aug 7, 2018 20:24 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	SaleCommon Stock	6,424	$109.81	$705,419.44	Disclosure SEC source: 0001562180-18-003502 · primarydocument.xml · nonDerivative · entry 3 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,455 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $109.29 to $110.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
August 07, 2018 Filed Aug 7, 2018 20:24 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	Exercise / conversionCommon Stock	3,000	$34.96	$104,880.00	Disclosure SEC source: 0001562180-18-003502 · primarydocument.xml · nonDerivative · entry 2 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
August 07, 2018 Filed Aug 7, 2018 20:24 UTC	BRIGHT HORIZONS FAMILY SOLUTIONS INC. BFAM · Entity 531	Exercise / conversionCommon Stock	2,272	$22.00	$49,984.00	Disclosure SEC source: 0001562180-18-003502 · primarydocument.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.